Rituximab (chimeric anti-CD20 antibody) for posttransplant lymphoproliferative disorder after solid organ transplantation in adults: Long-term experience from a single center

Transplantation

Volumn 80, Issue 12, 2005, Pages 1692-1698

  Jain, Ashokkumar B ^a,b   Marcos, Amadeo ^a   Pokharna, Renu ^a   Shapiro, Ron ^a   Fontes, Paulo A ^a   Marsh, Wallace ^a   Mohanka, Ravi ^b   Fung, John J ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Liver transplantation; Posttransplant lymphoproliferative disorder; Rituximab

Indexed keywords

ACICLOVIR; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; CD20 ANTIBODY; CHIMERIC ANTIBODY; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; PREDNISOLONE; RAPAMYCIN; RITUXIMAB; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CAUSE OF DEATH; CLINICAL ARTICLE; DRUG DOSE REDUCTION; EXCISION; FEMALE; FOLLOW UP; GRAFT FAILURE; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MALE; MESENTERY TUMOR; ORGAN TRANSPLANTATION; PANCREAS TRANSPLANTATION; PRIORITY JOURNAL; PROPHYLAXIS; RECURRENT DISEASE; SURVIVAL RATE; TREATMENT FAILURE; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 30144440127     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000185570.41571.df     Document Type: Article

References (27)

1. Penn I, Hammond W, Brettschneider L, Starzl TE. Malignant lymphomas in transplantation patients. Transplant Proc 1969; 1(1): 106.
2. Murray JE, Wilson RE, Tilney NL, et al. Discussion with Starzl, TE: Five years' experience in renal transplantation with immunosuppressive drugs: survival, function, complications, and the role of lymphocyte depletion by thoracic duct fistula. Ann Surg 1968; 168(3): 416.
3. Starzl TE, Nalesnik MA, Porter KA, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984; 1(8377): 583.
4. Jain A, Nalesnik M, Reyes J, et al. Posttransplant lymphoproliferative disorders in liver transplantation: a 20-year experience. Ann Surg 2002; 236 (4): 429.
5. Green M. Management of Epstein-Barr Virus-induced Post-transplant Lymphoproliferative Disease in Recipients of Solid Organ Transplantation. Am J Transplant 2001; 1(2): 103.
6. Nalesnik MA, Rao AS, Furukawa H, et al. Autologous lymphokine-activated killer cell therapy of Epstein-Barr virus-positive and -negative lymphoproliferative disorders arising in organ transplant recipients. Transplantation 1997; 63(9): 1200.
7. Cacciarelli TV, Green M, Jaffe R, et al. Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy. Transplantation 1998; 66 (8): 1047.
8. Davis TA, Maloney DG, Grillo-Lopez AJ, et al. Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a. Clin Cancer Res 2000; 6(7): 2644.
9. Grillo-Lopez AJ, White CA, Dallaire BK, et al. Rituximab: the first monoclonal antibody approved for the treatment of lymphoma. Curr Pharm Biotechnol 2000; 1(1): 1.
10. Nalesnik MA. The diverse pathology of post-transplant lymphoproliferative disorders: the importance of a standardized approach. Transpl Infect Dis 2001; 3(2): 88.
11. Swinnen L. Post-transplant lymphoproliferative disorders: implications for acquired immunodeficiency syndrome-associated malignancies. J Natl Cancer Inst Monagr 2001; 28: 38.
12. Colombat P, Salles G, Brousse N, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001; 97(1): 101.
13. Hainsworth JD, Burris HA, 3rd, Morrissey LH, et al. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood 2000; 95(10): 3052.
14. O'Dwyer, ME, Launder T, Rabkin JM, Nichols CR. Successful Treatment of Aggressive Post Transplant Lymphoproliferative Disorder using Rituximab. Leuk Lymphoma 2000; 39(3-4): 411.
15. Oertel SH, Anagnostopoulos I, Bechstein WO, et al. Treatment of posttransplant lymphoproliferative disorder with the anti-CD20 monoclonal antibody rituximab alone in an adult after liver transplantation: a new drug in therapy of patients with posttransplant lymphoproliferative disorder after solid organ transplantation? Transplantation 2000; 69(3): 430.
16. Zompi S, Tulliez M, Conti F, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with clonal lymphoproliferative disorders after orthotopic liver transplantation: a report of three cases. J Hepatol 2000; 32(3): 521.
17. Harris NL, Ferry JA, Swerdlow SH. Posttransplant lymphoproliferative disorders: summary of Society for Hematopathology Workshop. Semin Diagn Pathol 1997; 14(1): 8.
18. Jain A, Reyes J, Kashyap R, et al. What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients. Ann Surg 1999; 230(3): 441.
19. MilpiedN, VasseurB, ParquetN, et al. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol 2000; 11 Suppl 1: 113.
20. Ganne V, Siddiqi N, Kamaplath B, et al. Humanized anti-CD20 monoclonal antibody (Rituximab) treatment for post-transplant lymphoproliferative disorder. Clin Transplant 2003; 17(5): 417.
21. Ifthikharuddin JJ, Mieles LA, Rosenblatt JD, et al. CD-20 expression in post-transplant lymphoproliferative disorders: treatment with rituximab. Am J Hematol 2000; 65(2): 171.
22. Ohnishi K, Ohno R. [New antitumor drugs for non-Hodgkin's lymphoma]. Gan To Kagaku Ryoho 1998; 25(14): 2223.
23. Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17(1): 268.
24. Ghobrial IM, Habermann TM, Ristow KM, et al. Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era. Leuk Lymphoma 2005; 46(2): 191.
25. OrjuelaM, GrossTG, CheungYK, et al. A pilot study of chemoimmunotherapy (cyclophosphamide, prednisone, and rituximab) in patients with post-transplant lymphoproliferative disorder following solid organ transplantation. Clin Cancer Res 2003; 9 (10 Pt 2): 3945S.
26. Dotti G, Rambaldi A, Fiocchi R, et al. Anti-CD20 antibody (rituximab) administration in patients with late occurring lymphomas after solid organ transplant. Haematologica 2001; 86(6): 618.
27. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV. 6.1. Cancer risk after renal transplantation. Post-transplant lymphoproliferative disease (PTLD): prevention and treatment. Nephrol Dial Transplant 2002; 17 Suppl 4: 31.